Literature DB >> 16889542

C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings.

M Haas1, M H Rahman, L C Racusen, E S Kraus, S M Bagnasco, D L Segev, C E Simpkins, D S Warren, K E King, A A Zachary, R A Montgomery.   

Abstract

Biopsies of ABO-incompatible and positive crossmatch (HLA-incompatible) renal allografts were retrospectively examined to compare results of C4d and C3d staining, and the correlation between such staining and histologic findings suggestive of antibody-mediated rejection (AMR). A total of 75 biopsies (55 protocol, 17 for graft dysfunction, 3 for other indications) of 24 ABO-incompatible grafts and 244 biopsies (103 protocol, 129 for graft dysfunction, 12 for other indications) of 66 HLA-incompatible grafts were examined; all were stained for C4d and approximately 40% for C3d. In ABO-incompatible grafts, 80% of protocol biopsies and 59% performed for graft dysfunction showed C4d staining in peritubular capillaries (PTC); this staining was not correlated with neutrophil margination in PTC. In HLA-incompatible grafts, PTC C4d was present in 26% of protocol biopsies and 60% of biopsies for graft dysfunction; 92% of biopsies with >1+ (0-4+ scale), diffuse PTC C4d had > or =1+ margination and/or thrombotic microangiopathy (TMA), compared with 12% of C4d-negative biopsies. C3d was somewhat more predictive of margination than C4d in ABO-incompatible, but not HLA-incompatible, grafts. In summary, while PTC C4d deposition indicates probable AMR in biopsies of HLA-incompatible grafts, including protocol biopsies, there is no histologic evidence that C4d deposition is correlated with injury in most ABO-incompatible grafts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16889542     DOI: 10.1111/j.1600-6143.2006.01356.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  55 in total

Review 1.  Histopathological diagnosis of acute and chronic rejection in pediatric kidney transplantation.

Authors:  Verena Bröcker; Michael Mengel
Journal:  Pediatr Nephrol       Date:  2013-10-19       Impact factor: 3.714

2.  Revisiting traditional risk factors for rejection and graft loss after kidney transplantation.

Authors:  T B Dunn; H Noreen; K Gillingham; D Maurer; O G Ozturk; T L Pruett; R A Bray; H M Gebel; A J Matas
Journal:  Am J Transplant       Date:  2011-08-03       Impact factor: 8.086

3.  C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts.

Authors:  Mark Haas; Dorry L Segev; Lorraine C Racusen; Serena M Bagnasco; Jayme E Locke; Daniel S Warren; Christopher E Simpkins; Diane Lepley; Karen E King; Edward S Kraus; Robert A Montgomery
Journal:  J Am Soc Nephrol       Date:  2008-09-05       Impact factor: 10.121

4.  Vienna experience of ABO-incompatible living-donor kidney transplantation.

Authors:  Michael Haidinger; Sabine Schmaldienst; Günther Körmöczi; Heinz Regele; Afschin Soleiman; Dieter Schwartz; Kurt Derfler; Rudolf Steininger; Ferdinand Mühlbacher; Georg A Böhmig
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 5.  Antibody-mediated rejection: emergence of animal models to answer clinical questions.

Authors:  William M Baldwin; Anna Valujskikh; Robert L Fairchild
Journal:  Am J Transplant       Date:  2010-03-19       Impact factor: 8.086

Review 6.  Chronic alloantibody mediated rejection.

Authors:  R Neal Smith; Robert B Colvin
Journal:  Semin Immunol       Date:  2011-11-02       Impact factor: 11.130

Review 7.  New concepts of complement in allorecognition and graft rejection.

Authors:  Barbara A Wasowska; Chih-Yuan Lee; Marc K Halushka; William M Baldwin
Journal:  Cell Immunol       Date:  2007-10-24       Impact factor: 4.868

8.  An experimental model of acute humoral rejection of renal allografts associated with concomitant cellular rejection.

Authors:  Alice Bickerstaff; Ronald Pelletier; Jiao-Jing Wang; Gyongyi Nadasdy; Nicholas DiPaola; Charles Orosz; Anjali Satoskar; Gregg Hadley; Tibor Nadasdy
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

9.  Pathologic findings in lung allografts with anti-HLA antibodies.

Authors:  Matthew M DeNicola; Sam S Weigt; John A Belperio; Elaine F Reed; David J Ross; W Dean Wallace
Journal:  J Heart Lung Transplant       Date:  2013-01-10       Impact factor: 10.247

Review 10.  Strategies to overcome the ABO barrier in kidney transplantation.

Authors:  Georg A Böhmig; Andreas M Farkas; Farsad Eskandary; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2015-09-01       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.